{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:30Z","timestamp":1790624430035,"version":"4.1.0"},"reference-count":120,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone\u2014R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R\/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL.<\/jats:p>","DOI":"10.3390\/cancers12010185","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?"],"prefix":"10.3390","volume":"12","author":[{"given":"Nicoletta","family":"Coccaro","sequence":"first","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Anelli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zagaria","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-99-112403","article-title":"Excellent Outcome of Young Patients (18\u201360 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl\/GLA","volume":"132","author":"Poeschel","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V124.21.630.630","article-title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)","volume":"124","author":"McMillan","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Schmitz","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bachanova, V., Perales, M.-A., and Abramson, J.S. (2019). Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Rev., 100640.","DOI":"10.1016\/j.blre.2019.100640"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin\u2019s Lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma","volume":"208","author":"Muris","year":"2006","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortiu","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Perfecto-Avalos, Y., Garcia-Gonzalez, A., Hernandez-Reynoso, A., S\u00e1nchez-Ante, G., Ortiz-Hidalgo, C., Scott, S.P., Fuentes-Aguilar, R.Q., DIaz-Dominguez, R., Le\u00f3n-Mart\u00ednez, G., and Velasco-Vales, V. (2019). Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. J. Transl. Med., 17.","DOI":"10.1186\/s12967-019-1951-y"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2017.166827","article-title":"Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay","volume":"102","author":"Jais","year":"2017","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Loeffler-Wirth, H., Kreuz, M., Hopp, L., Arakelyan, A., Haake, A., Cogliatti, S.B., Feller, A.C., Hansmann, M.L., Lenze, D., and M\u00f6ller, P. (2019). A modular transcriptome map of mature B cell lymphomas. Genome Med., 11.","DOI":"10.1186\/s13073-019-0637-7"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","article-title":"Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis","volume":"33","author":"Falgreen","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/bloodadvances.2018017988","article-title":"A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology","volume":"2","author":"Michaelsen","year":"2018","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbcan.2018.01.001","article-title":"Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment","volume":"1869","author":"Guo","year":"2018","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: A GELA\/LYSA study","volume":"126","author":"Baia","year":"2015","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of Epstein-Barr virus infection in de Novo diffuse large B-cell lymphoma in western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/modpathol.2016.178","article-title":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma","volume":"30","author":"Wang","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell\u2013inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/mc.23074","article-title":"Aberrant ERG expression associates with downregulation of miR-4638-5p and selected genomic alterations in a subset of diffuse large B-cell lymphoma","volume":"58","author":"Zhang","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_47","first-page":"987","article-title":"Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: Data from the phase III GOYA study","volume":"329","author":"Bolen","year":"2019","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/sj.leu.2404784","article-title":"Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma","volume":"21","author":"Storlazzi","year":"2007","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Vermaat, J.S., Somers, S.F., de Wreede, L.C., Kraan, W., de Groen, R.A.L., Schrader, A.M.R., Kerver, E.D., Scheepstra, C.G., Beerenschot, H., and Deenik, W. (2019). MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis. Haematologica.","DOI":"10.3324\/haematol.2018.214122"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jain, N., Hartert, K., Tadros, S., Fiskus, W., Havranek, O., Ma, M.C.J., Bouska, A., Heavican, T., Kumar, D., and Deng, Q. (2019). Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aav5599"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Intlekofer, A.M., Joffe, E., Batlevi, C.L., Hilden, P., He, J., Seshan, V.E., Zelenetz, A.D., Palomba, M.L., Moskowitz, C.H., and Portlock, C. (2018). Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J., 8.","DOI":"10.1038\/s41408-018-0089-0"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/s41375-019-0509-6","article-title":"Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes","volume":"33","author":"Alkodsi","year":"2019","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Arthur, S.E., Jiang, A., Grande, B.M., Alcaide, M., Cojocaru, R., Rushton, C.K., Mottok, A., Hilton, L.K., Lat, P.K., and Zhao, E.Y. (2018). Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-06354-3"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, Y., Feng, W., and Liu, P. (2019). Genomic pattern of intratumor heterogeneity predicts the risk of progression in early stage diffuse large B-cell lymphoma. Carcinogenesis, 11.","DOI":"10.1093\/carcin\/bgz068"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of Follicular Lymphoma Transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Rinc\u00f3n, J., M\u00e9ndez, M., G\u00f3mez, S., Garc\u00eda, J.F., Mart\u00edn, P., Bellas, C., Pedrosa, L., Rodr\u00edguez-Pinilla, S.M., Camacho, F.I., and Quero, C. (2019). Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212813"},{"key":"ref_60","first-page":"432","article-title":"Deep-sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas","volume":"15","author":"Jiang","year":"2014","journal-title":"Genome Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Nijland, M., Seitz, A., Terpstra, M., van Imhoff, G.W., Kluin, P.M., van Meerten, T., Atayar, \u00c7., van Kempen, L.C., Diepstra, A., and Kok, K. (2018). Mutational evolution in relapsed diffuse large B-cell lymphoma. Cancers (Basel)., 10.","DOI":"10.3390\/cancers10110459"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fornecker, L.M., Muller, L., Bertrand, F., Paul, N., Pichot, A., Herbrecht, R., Chenard, M.P., Mauvieux, L., Vallat, L., and Bahram, S. (2019). Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-37273-4"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hon.4_2629","article-title":"Identifying Mutations Enriched in Relapsed-Refractory Dlbcl to Derive Genetic Factors Underlying Treatment Resistance","volume":"37","author":"Rushton","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/leu.2010.302","article-title":"The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma","volume":"25","author":"Ruminy","year":"2011","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.18632\/oncotarget.653","article-title":"Recurrent targets of aberrant somatic hypermutation in lymphoma","volume":"3","author":"Khodabakhshi","year":"2012","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng.2007.35","article-title":"AID is required for germinal center-derived lymphomagenesis","volume":"40","author":"Pasqualucci","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/his.13316","article-title":"MYC expression and translocation analyses in low-grade and transformed follicular lymphoma","volume":"71","author":"Aukema","year":"2017","journal-title":"Histopathology"},{"key":"ref_76","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., and Stein, H.T.J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: Defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Dave, K., Sur, I., Yan, J., Zhang, J., Kaasinen, E., Zhong, F., Blaas, L., Li, X., Kharazi, S., and Gustafsson, C. (2017). Mice deficient of Myc super-enhancer region reveal differential control mechanism between normal and pathological growth. Elife, 6.","DOI":"10.7554\/eLife.23382"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature25193","article-title":"A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies","volume":"553","author":"Bahr","year":"2018","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.emboj.7600217","article-title":"Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7","volume":"23","author":"Yada","year":"2004","journal-title":"EMBO J."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gallardo, M., Malaney, P., Aitken, M.J.L., Zhang, X., Link, T.M., Shah, V., Alybayev, S., Wu, M.-H., Pageon, L.R., and Ma, H. (2019). Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. JNCI J. Natl. Cancer Inst., 5.","DOI":"10.1093\/jnci\/djz078"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","article-title":"High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology","volume":"2","author":"Chong","year":"2018","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Rosenwald, A., Bens, S., Advani, R., Barrans, S., Copie-Bergman, C., Elsensohn, M.-H., Natkunam, Y., Calaminici, M., Sander, B., and Baia, M. (2019). Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. J. Clin. Oncol., 11.","DOI":"10.1200\/JCO.19.00743"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","article-title":"Double-hit lymphomas: Current paradigms and novel treatment approaches","volume":"2014","author":"Dunleavy","year":"2014","journal-title":"Hematology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2018.204958","article-title":"Targeting BCL2 with venetoclax is a promising therapeutic strategy for \u201cdouble-proteinexpression\u201d lymphoma with MYC and BCL2 rearrangements","volume":"104","author":"Uchida","year":"2019","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2019-129783","article-title":"First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed\/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"134","author":"Carneiro","year":"2019","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Scherer, F., Kurtz, D.M., Newman, A.M., Stehr, H., Craig, A.F.M., Esfahani, M.S., Lovejoy, A.F., Chabon, J.J., Klass, D.M., and Liu, C.L. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med., 8.","DOI":"10.1126\/scitranslmed.aai8545"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","article-title":"Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma","volume":"57","author":"Camus","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7150\/jca.27615","article-title":"Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mondello, P., and Mian, M. (2019). Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. Hematol. Oncol., 10.","DOI":"10.1002\/hon.2613"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.hoc.2019.03.006","article-title":"Targeting Biology in Non-Hodgkin Lymphoma","volume":"33","author":"Narkhede","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"346","DOI":"10.18632\/oncotarget.20378","article-title":"Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/17474086.2017.1268046","article-title":"New targeted therapies for malignant lymphoma based on molecular heterogeneity","volume":"10","author":"Horn","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"De Jong, M.R.W., Visser, L., Huls, G., Diepstra, A., Van Vugt, M., Ammatuna, E., van Rijn, R.S., Vellenga, E., Van Den Berg, A., and Fehrmann, R.S.N. (2018). Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193098"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Futur. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-08-869503","article-title":"Combinations or sequences of targeted agents in CLL: Is the whole greater than the sum of its parts (Aristotle, 360 BC)?","volume":"133","author":"Yazdy","year":"2019","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2012.10.014","article-title":"A missing link in genotype-directed cancer therapy","volume":"151","author":"Bernards","year":"2012","journal-title":"Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2013.74","article-title":"Signaling cross-talk in the resistance to HER family receptor targeted therapy","volume":"33","author":"Yamaguchi","year":"2014","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Palmer, A.C., Chidley, C., and Sorger, P. (2018). Drugs in a Curative Combination Therapy for Lymphoma Exhibit Low Cross-Resistance But Not Pharmacological Synergy. SSRN Electron. J.","DOI":"10.2139\/ssrn.3249463"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","article-title":"DeepSynergy: Predicting anti-cancer drug synergy with Deep Learning","volume":"34","author":"Preuer","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lee, J.H., Kim, D.G., Bae, T.J., Rho, K., Kim, J.T., Lee, J.J., Jang, Y., Kim, B.C., Park, K.M., and Kim, S. (2012). CDA: Combinatorial drug discovery using transcriptional response modules. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042573"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tang, J., Karhinen, L., Xu, T., Szwajda, A., Yadav, B., Wennerberg, K., and Aittokallio, T. (2013). Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. PLoS Comput. Biol., 9.","DOI":"10.1371\/journal.pcbi.1003226"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1093\/bioinformatics\/btz109","article-title":"Driver network as a biomarker: Systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction","volume":"35","author":"Huang","year":"2019","journal-title":"Bioinformatics"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:19:30Z","timestamp":1760361570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["cancers12010185"],"URL":"https:\/\/doi.org\/10.3390\/cancers12010185","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,11]]}}}